1-(2-甲基-1,3-苯并恶唑-6-基)-3-(1,5-萘啶-4-基)脲 | 249889-64-3

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1-(2-甲基-1,3-苯并恶唑-6-基)-3-(1,5-萘啶-4-基)脲
• 中文别名: 密草通
• 英文名称: SB 334867A
• 英文别名: SB-334867；SB334867；SB 334867；OX1RA；1-(2-methyl-benzoxazol-6-yl)-3-[1,5]naphthyridin-4-yl-urea hydrochloride；1-(2-methylbenzoxazol-6-yl)-3-([1,5]naphthyridin-4-yl)urea hydrochloride；N-(2-Methylbenzoxazol-6-yl)-N'-(1,5-naphthyridin-4-yl)urea hydrochloride；1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea;hydrochloride
• CAS: 249889-64-3
• 化学式: C₁₇H₁₃N₅O₂*ClH
• 分子量: 355.783
• InChiKey: BKZHSJNLPPAJKB-UHFFFAOYSA-N

物化性质

• 熔点：
  >235°C (dec.)
• 溶解度：
  可溶于二氯甲烷（少许）、DMSO（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  4.15
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  92.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(2-甲基-1,3-苯并恶唑-6-基)-3-(1,5-萘啶-4-基)脲 在 水 作用下， 反应 7305.0h， 生成 1-(2-hydroxy-4-{[(1,5-naphthyridin-4-yl)carbamoyl]amino}phenyl)acetamide hydrochloride
  参考文献：
  名称：

  Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: Possible confounding effects on in vivo and in vitro studies

  摘要：

  SB-334867 has been an important ligand for the study of the orexin 1 (OX1) receptor due to its high OX1/OX2 selectivity and bioavailability. This ligand however, contains a 2-methylbenzoxazole ring system which is known to undergo hydrolysis, particularly under acidic or basic conditions. The possibility that SB-334867 would be susceptible to significant hydrolysis was evaluated in various formulations and in the solid state. SB-334867 was found to be unstable under conditions commonly employed to prepare stock solutions for in vitro and in vivo studies. In addition, and most alarmingly, the hydrochloride salt of SB-334867 was found to quantitatively decompose to an OX1-inactive product even in the solid state. These findings combine to suggest that studies using SB-334867 (and any other 2-methylbenzoxazole-containing compound) should be performed with great care to avoid the confounding effects of the rapid hydrolytic decomposition of this susceptible structure. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.08.109
• 作为产物：
  描述：

  4-羟基-1,5-萘啶 在 吡啶 、 叠氮磷酸二苯酯 、 盐酸丙胺 、 三溴化磷 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 8.67h， 生成 1-(2-甲基-1,3-苯并恶唑-6-基)-3-(1,5-萘啶-4-基)脲
  参考文献：
  名称：

  Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: Possible confounding effects on in vivo and in vitro studies

  摘要：

  SB-334867 has been an important ligand for the study of the orexin 1 (OX1) receptor due to its high OX1/OX2 selectivity and bioavailability. This ligand however, contains a 2-methylbenzoxazole ring system which is known to undergo hydrolysis, particularly under acidic or basic conditions. The possibility that SB-334867 would be susceptible to significant hydrolysis was evaluated in various formulations and in the solid state. SB-334867 was found to be unstable under conditions commonly employed to prepare stock solutions for in vitro and in vivo studies. In addition, and most alarmingly, the hydrochloride salt of SB-334867 was found to quantitatively decompose to an OX1-inactive product even in the solid state. These findings combine to suggest that studies using SB-334867 (and any other 2-methylbenzoxazole-containing compound) should be performed with great care to avoid the confounding effects of the rapid hydrolytic decomposition of this susceptible structure. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.08.109

文献信息

• ANTIANXIETY DRUGS AND A METHOD OF SCREENING THE SAME
  申请人：Sawai Toru

  公开号：US20070160538A1

  公开（公告）日：2007-07-12

  An anxiolytic drug of the invention comprises an orexin receptor antagonist, a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient. A method for screening a compound having an anxiolytic action of the invention comprises a step of using orexin-A.

  本发明的抗焦虑药物包括作为活性成分的食欲素受体拮抗剂、其药理上可接受的盐或其溶剂化物。本发明用于筛选具有抗焦虑作用的化合物的方法包括使用食欲素-A的步骤。
• Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof
  申请人：JAEHNE Gerhard

  公开号：US20110178134A1

  公开（公告）日：2011-07-21

  The invention relates to compounds of formula (I) wherein the groups have stated meanings, and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

  本发明涉及具有所述意义的公式（I）的化合物，以及它们的生理相容性盐。所述化合物适用于例如作为抗肥胖药物和治疗心血管代谢综合征。
• CARBAMOYLBENZOTRIAZOLE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES
  申请人：Petry Stefan

  公开号：US20080287503A1

  公开（公告）日：2008-11-20

  The invention relates to carbamoylbenzotriazole derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.

  这项发明涉及一般式(I)的氨基甲酰基苯并三唑衍生物，其在描述中被定义，以及它们的药用盐和作为药物的用途。
• AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES
  申请人：Petry Stefan

  公开号：US20130157941A1

  公开（公告）日：2013-06-20

  The present invention relates to azolopyridin-3-one derivatives of the general formula (I) with the meanings specified in the description, to their pharmaceutically usable salts and to their use as drug substances.

  本发明涉及通式（I）所示的咪唑吡啶-3-酮衍生物，其含义如描述中所指定的，以及它们的药用盐和作为药物物质的用途。
• Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof
  申请人：JAEHNE Gerhard

  公开号：US20110053947A1

  公开（公告）日：2011-03-03

  The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.

  本发明涉及具有公式（I）的化合物，其中R和R'、A、D、E、G、L、p以及R1至R10具有所述含义，以及它们的生理相容性盐。所述化合物例如可作为抗肥胖药物使用。